Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...

Discover how Akero Therapeutics' EFX outshines competitors in MASH treatment, with groundbreaking results and strong ...

Corebridge Financial Inc. lowered its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 7.0% in ...

Insiders have lately been showing their love for these three biotech stocks, two tech stocks, and a utility stock with huge ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money ...